Trillium Therapeutics Inc.
CD47 BLOCKADE WITH RADIATION THERAPY

Last updated:

Abstract:

This patent application relates to the treatment of cancer and other diseases that have a CD47+ phenotype. Treatment involves the use of radiation and a CD47-binding agent, preferably a CD47-binding form of human signal regulatory protein alpha (SIRPa) that inhibits activation of the CD47/SIRPa axis and mediates phagocytosis of CD47+ disease cells. An anti-cancer effect of a CD47 blocking agent is enhanced when combined with radiation therapy. The anti-cancer effect of a CD47 blocking agent such as SIRPaFc is enhanced when combined with radiation therapy.

Status:
Application
Type:

Utility

Filling date:

5 Nov 2018

Issue date:

12 Aug 2021